MNPR · Monopar Therapeutics · Proposed Sales
Market Cap
$727.06M
Shares
6.71M
Notices of intent to sell restricted or control shares, filed with the SEC on Form 144 by insiders and affiliates. A Form 144 signals a planned sale — it does not confirm the shares were actually sold.
| Filed | Seller | Relationship | Shares | Approx. Sale | Broker |
|---|---|---|---|---|---|
| 2026-08-26 | PATRICE RIOUX | Acting Chief Medical Officer | 1 | 2026-08-26 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-26 | KIM TSUCHIMOTO | Director | 8,180 | 2026-08-26 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-25 | RAYMOND WILLIAM ANDERSON | Director | 6,284 | 2026-08-25 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-12-19 | Arthur Klausner | Board Member | 5,121 | 2025-12-18 | MLPFS |
| 2025-07-14 | Robinson Chandler | Officer, Director | 16,800 | 2025-07-14 | Merrill Lynch Pierce Fenner & Smith Inc. |
| 2025-07-14 | Tsuchimoto Kim R | Director | 8,904 | 2025-07-14 | Merrill Lynch Pierce Fenner & Smith Inc. |
| 2025-07-14 | STARR CHRISTOPHER M | Director | 16,800 | 2025-07-14 | Merrill Lynch Pierce Fenner & Smith Inc. |
| 2025-04-02 | Tactic Pharma LLC | 10% Stockholder | 33,334 | 2025-04-02 | Merrill Lynch, Pierce, Fenner & Smith, Inc. |
Showing 1–8 of 8 filings